Two Sigma Investments LP Grows Stake in Replimune Group, Inc. (NASDAQ:REPL)

Two Sigma Investments LP lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 18.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 212,586 shares of the company's stock after buying an additional 33,346 shares during the period. Two Sigma Investments LP owned about 0.31% of Replimune Group worth $2,574,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Sterling Capital Management LLC raised its stake in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after buying an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd raised its stake in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock worth $100,000 after buying an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Replimune Group during the 4th quarter worth approximately $117,000. Finally, Quantinno Capital Management LP purchased a new position in shares of Replimune Group during the 4th quarter worth approximately $127,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

NASDAQ:REPL traded up $0.14 during trading hours on Tuesday, reaching $9.71. 1,003,355 shares of the company traded hands, compared to its average volume of 944,685. Replimune Group, Inc. has a 1-year low of $4.93 and a 1-year high of $17.00. The firm's 50-day moving average is $8.37 and its 200-day moving average is $11.07. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock has a market cap of $748.51 million, a P/E ratio of -3.16 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the business posted ($0.25) earnings per share. Equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, CAO Andrew Schwendenman sold 3,287 shares of the firm's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $26,460.35. Following the transaction, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Philip Astley-Sparke sold 32,279 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the transaction, the director now directly owns 1,405,071 shares in the company, valued at $11,324,872.26. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 over the last quarter. 8.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on REPL shares. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler increased their target price on Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a report on Monday. Finally, HC Wainwright increased their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $19.75.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.